Mark Pollack to Drug Administration Schedule
This is a "connection" page, showing publications Mark Pollack has written about Drug Administration Schedule.
Connection Strength
0.822
-
A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan; 171(1):44-53.
Score: 0.116
-
Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008 Oct; 42(12):1042-9.
Score: 0.077
-
An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006 Mar; 67(3):381-5.
Score: 0.067
-
The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005 Nov; 66(11):1401-8.
Score: 0.066
-
Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. J Clin Psychiatry. 2005; 66 Suppl 2:21-7.
Score: 0.062
-
An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004 Sep; 65(9):1219-22.
Score: 0.061
-
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
Score: 0.060
-
Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001 May; 62(5):350-7.
Score: 0.048
-
Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2020 06 01; 3(6):e206777.
Score: 0.045
-
Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998 Nov; 55(11):1010-6.
Score: 0.040
-
Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998 Jul; 155(7):992-3.
Score: 0.040
-
Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997; 58 Suppl 11:19-23.
Score: 0.036
-
Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008 Jun; 13(6):522-7.
Score: 0.020
-
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006 Mar; 63(3):298-304.
Score: 0.017
-
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005 Sep; 62(9):1022-30.
Score: 0.016
-
Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 2002 Mar-Apr; 10(2):109-14.
Score: 0.013
-
Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand. 2001 Oct; 104(4):289-98.
Score: 0.012
-
Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999 May; 156(5):756-60.
Score: 0.010
-
Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998 Nov; 155(11):1570-7.
Score: 0.010
-
Clonazepam for the treatment of social phobia. J Clin Psychiatry. 1990 Nov; 51(11):470-2.
Score: 0.006